Plasma L5 levels are elevated in ischemic stroke patients and enhance platelet aggregation

Blood

Volumn 127, Issue 10, 2016, Pages 1336-1345

  Shen, Ming Yi ^a,c   Chen, Fang Yu ^a,b   Hsu, Jing Fang ^a,d   Fu, Ru Huei ^a   Chang, Chia Ming ^a,b   Chang, Chiz Tzung ^a   Liu, Chung Hsiang ^b   Wu, Jia Rong ^a   Lee, An Sheng ^b,e   Chan, Hua Chen ^d   Sheu, Joen Rong ^c   Lin, Shinn Zong ^a,b,i   Shyu, Woei Cherng ^a,b   Sawamura, Tatsuya ^f,h   Chang, Kuan Cheng ^a,b   Hsu, Chung Y ^a,b   Chen, Chu Huang ^a,d,g,j  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c Departments of Medicine   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e MACKAY MEDICAL COLLEGE   (Taiwan)

^f SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g TEXAS HEART INSTITUTE   (United States)

^h New York Heart Research Foundation   (United States)

ⁱ KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^j CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; I KAPPA B ALPHA; I KAPPA B BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; L5 PROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PEPTIDES AND PROTEINS; STRESS ACTIVATED PROTEIN KINASE 1; UNCLASSIFIED DRUG; I KAPPA B KINASE; IKBKB PROTEIN, MOUSE; IKK2 PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN; LOW-DENSITY LIPOPROTEIN L5, HUMAN; OLR1 PROTEIN, HUMAN; OLR1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION; ANIMAL; BLOOD; BRAIN ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; DISEASE MODEL; FEMALE; KNOCKOUT MOUSE; MALE; METABOLISM; OCCLUSIVE CEREBROVASCULAR DISEASE; PATHOLOGY; SIGNAL TRANSDUCTION;

AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; I-KAPPA B KINASE; INTRACRANIAL ARTERIOSCLEROSIS; INTRACRANIAL THROMBOSIS; LIPOPROTEINS, LDL; MALE; MICE; MICE, KNOCKOUT; PLATELET AGGREGATION; SCAVENGER RECEPTORS, CLASS E; SIGNAL TRANSDUCTION; STROKE;

EID: 84960896552     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-05-646117     Document Type: Article

References (52)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367(9524): 1747-1757.
2. Stoll G, Kleinschnitz C, Nieswandt B. Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment. Blood. 2008;112(9):3555-3562.
3. Beal CC. Gender and stroke symptoms: A review of the current literature. J Neurosci Nurs. 2010; 42(2):80-87.
4. Wilterdink JL, Easton JD. Vascular event rates in patients with atherosclerotic cerebrovascular disease. Arch Neurol. 1992;49(8):857-863.
5. Zheng L, Vinters HV, Mack WJ, Zarow C, Ellis WG, Chui HC. Cerebral atherosclerosis is associated with cystic infarcts and microinfarcts but not Alzheimer pathologic changes. Stroke. 2013;44(10):2835-2841.
6. Freedman JE. Molecular regulation of plateletdependent thrombosis. Circulation. 2005;112(17): 2725-2734.
7. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357(24): 2482-2494.
8. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8(11):1227-1234.
9. Shen MY, Hsiao G, Fong TH, et al. Amyloid beta peptide-Activated signal pathways in human platelets. Eur J Pharmacol. 2008;588(2-3): 259-266.
10. Li QX, Berndt MC, Bush AI, et al. Membraneassociated forms of the beta A4 amyloid protein precursor of Alzheimer's disease in human platelet and brain: surface expression on the activated human platelet. Blood. 1994;84(1): 133-142.
11. Shen MY, Hsiao G, Fong TH, et al. Expression of amyloid beta peptide in human platelets: pivotal role of the phospholipase Cgamma2-protein kinase C pathway in platelet activation. Pharmacol Res. 2008;57(2):151-158.
12. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. Beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature. 1996; 380(6570):168-171.
13. Greenberg SM, Vonsattel JP. Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy. Stroke. 1997;28(7): 1418-1422.
14. Lee PH, Bang OY, Hwang EM, et al. Circulating beta amyloid protein is elevated in patients with acute ischemic stroke. J Neural Transm (Vienna). 2005;112(10):1371-1379.
15. Chen CH, Jiang T, Yang JH, et al. Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation. 2003;107(16): 2102-2108.
16. Chan HC, Ke LY, Chu CS, et al. Highly electronegative LDL from patients with STelevation myocardial infarction triggers platelet activation and aggregation. Blood. 2013;122(22): 3632-3641.
17. Sawamura T, Kume N, Aoyama T, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature. 1997;386(6620):73-77.
18. Lu J, Yang JH, Burns AR, et al. Mediation of electronegative low-density lipoprotein signaling by LOX-1: A possible mechanism of endothelial apoptosis. Circ Res. 2009;104(5):619-627.
19. Schwarz DA, Barry G, Mackay KB, et al. Identification of differentially expressed genes induced by transient ischemic stroke. Brain Res Mol Brain Res. 2002;101(1-2):12-22.
20. Lu J, Jiang W, Yang JH, et al. Electronegative LDL impairs vascular endothelial cell integrity in diabetes by disrupting fibroblast growth factor 2 (FGF2) autoregulation. Diabetes. 2008;57(1): 158-166.
21. Wang G-J, Chang C-T, Yang C-Y, Chen C-H. Negatively charged L5 as a naturally occurring atherogenic low-density lipoprotein. BioMedicine (Netherlands). 2012;2(4):147-154.
22. Nichols TC. Bad cholesterol breaking really bad. Blood. 2013;122(22):3551-3553.
23. Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammationassociated cancer. Nature. 2004;431(7007): 461-466.
24. Herrmann O, Baumann B, de Lorenzi R, et al. IKK mediates ischemia-induced neuronal death. Nat Med. 2005;11(12):1322-1329.
25. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell. 1997;91(2): 243-252.
26. Aviram M. Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patients. Biochem Med. 1983;30(1):111-118.
27. Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K. Determination of beta-Amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J Proteome Res. 2006;5(4):1010-1016.
28. Mehta JL, Sanada N, Hu CP, et al. Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res. 2007; 100(11):1634-1642.
29. Hsiao G, Lee JJ, Chen YC, et al. Neuroprotective effects of PMC, a potent alpha-Tocopherol derivative, in brain ischemia-reperfusion: reduced neutrophil activation and anti-oxidant actions. Biochem Pharmacol. 2007;73(5):682-693.
30. Zhao BQ, Chauhan AK, Canault M, et al. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood. 2009;114(15):3329-3334.
31. Boü et V, Freret T, Toutain J, Divoux D, Boulouard M, Schumann-Bard P. Sensorimotor and cognitive deficits after transient middle cerebral artery occlusion in the mouse. Exp Neurol. 2007; 203(2):555-567.
32. Bouet V, Boulouard M, Toutain J, et al. The adhesive removal test: A sensitive method to assess sensorimotor deficits in mice. Nat Protoc. 2009;4(10):1560-1564.
33. Choudhri TF, Hoh BL, Zerwes HG, et al. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation. J Clin Invest. 1998;102(7):1301-1310.
34. Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, Stoll G. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation. 2007;115(17):2323-2330.
35. Karatas H, Erdener SE, Gursoy-Ozdemir Y, et al. Thrombotic distal middle cerebral artery occlusion produced by topical FeCl(3) application: A novel model suitable for intravital microscopy and thrombolysis studies. J Cereb Blood Flow Metab. 2011;31(6):1452-1460.
36. Farrehi PM, Ozaki CK, Carmeliet P, Fay WP. Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation. 1998;97(10):1002-1008.
37. Chen WF, Lee JJ, Chang CC, Lin KH, Wang SH, Sheu JR. Platelet protease-Activated receptor (PAR)4, but not PAR1, associated with neutral sphingomyelinase responsible for thrombinstimulated ceramide-NF-kB signaling in human platelets. Haematologica. 2013;98(5):793-801.
38. Karim ZA, Zhang J, Banerjee M, et al. IkB kinase phosphorylation of SNAP-23 controls platelet secretion. Blood. 2013;121(22):4567-4574.
39. Gardener H, Della Morte D, Elkind MS, Sacco RL, Rundek T. Lipids and carotid plaque in the Northern Manhattan Study (NOMAS). BMC Cardiovasc Disord. 2009;9:55.
40. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347): 317-325.
41. Lee AS, Wang GJ, Chan HC, et al. Electronegative low-density lipoprotein induces cardiomyocyte apoptosis indirectly through endothelial cell-released chemokines. Apoptosis. 2012;17(9):1009-1018.
42. Chang K-C, Wang Y-C, Chang S-S, et al. Expression of the highly electronegative LDL receptor LOX-1 is increased in thrombi of STEMI patients [abstract]. Circulation. 2012;126(suppl 21). Abstract 13127.
43. Nagase M, Hirose S, Sawamura T, Masaki T, Fujita T. Enhanced expression of endothelial oxidized low-density lipoprotein receptor (LOX-1) in hypertensive rats. Biochem Biophys Res Commun. 1997;237(3):496-498.
44. Fukui M, Tanaka M, Senmaru T, et al. LOX-1 is a novel marker for peripheral artery disease in patients with type 2 diabetes. Metabolism. 2013; 62(7):935-938.
45. Chen M, Kakutani M, Minami M, et al. Increased expression of lectin-like oxidized low density lipoprotein receptor-1 in initial atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol. 2000; 20(4):1107-1115.
46. Li D, Williams V, Liu L, et al. LOX-1 inhibition in myocardial ischemia-reperfusion injury: modulation of MMP-1 and inflammation. Am J Physiol Heart Circ Physiol. 2002;283(5): H1795-H1801.
47. Nakano A, Inoue N, Sato Y, et al. LOX-1 mediates vascular lipid retention under hypertensive state. J Hypertens. 2010;28(6):1273-1280.
48. Morawietz H. LOX-1 receptor as a novel target in endothelial dysfunction and atherosclerosis [in German]. Dtsch Med Wochenschr. 2010;135(7): 308-312.
49. Hsu MJ, Sheu JR, Lin CH, Shen MY, Hsu CY. Mitochondrial mechanisms in amyloid beta peptide-induced cerebrovascular degeneration. Biochim Biophys Acta. 2010;1800(3):290-296.
50. Baeuerle PA, Baltimore D. I kappa B: A specific inhibitor of the NF-kappa B transcription factor. Science. 1988;242(4878):540-546.
51. Beaulieu LM, Freedman JE. NFkappaB regulation of platelet function: no nucleus, no genes, no problem? J Thromb Haemost. 2009;7(8): 1329-1332.
52. Malaver E, Romaniuk MA, D'Atri LP, et al. NF-kappaB inhibitors impair platelet activation responses. J Thromb Haemost. 2009;7(8): 1333-1343.